PAM4 在胰腺癌管理中的作用：诊断、放射免疫检测和放射免疫治疗。
The role of PAM4 in the management of pancreatic cancer: diagnosis, radioimmunodetection, and radioimmunotherapy.
机构信息
Department of Medical Oncology, The First Affiliated Hospital of Xi'an Jiaotong University Medical Center, Xi'an, Shannxi 710061, China.
出版信息
J Immunol Res. 2014;2014:268479. doi: 10.1155/2014/268479. Epub 2014 Apr 10.
Abstract
PAM4, a new monoclonal antibody (MAb) known as clivatuzumab, is highly reactive with pancreatic cancer and precursor lesions. It is absent from the normal tissues and has limited reactivity with nonpancreatic cancer. The detailed characteristic of the PAM4 epitope is unknown but recent studies have shown that it is dependent on MUC1 glycosylation status. The limited PAM4 expression pattern makes it an attractive candidate for management of pancreatic adenocarcinoma. In addition, PAM4 is a serum biomarker for diagnosis of pancreatic cancer. Several different radiolabeled immunodiagnostic and immunotherapeutic agents of PAM4 have been developed and some are being evaluated in preclinical and/or clinical studies. The review will focus on PAM4 and its potential utility for the diagnosis, radioimmunodetection, and radioimmunotherapy of pancreatic cancer.
摘要
PAM4 是一种新的单克隆抗体（MAb），称为 clivatuzumab，与胰腺癌和前体病变高度反应。它不存在于正常组织中，与非胰腺癌的反应性有限。PAM4 表位的详细特征尚不清楚，但最近的研究表明它依赖于 MUC1 糖基化状态。有限的 PAM4 表达模式使其成为管理胰腺腺癌的有吸引力的候选物。此外，PAM4 是诊断胰腺癌的血清生物标志物。已经开发了几种不同的放射性标记免疫诊断和免疫治疗剂的 PAM4，并且一些正在进行临床前和/或临床研究评估。该综述将重点介绍 PAM4 及其在胰腺癌的诊断、放射免疫检测和放射免疫治疗中的潜在用途。
相似文献
1
The role of PAM4 in the management of pancreatic cancer: diagnosis, radioimmunodetection, and radioimmunotherapy.PAM4 在胰腺癌管理中的作用：诊断、放射免疫检测和放射免疫治疗。
J Immunol Res. 2014;2014:268479. doi: 10.1155/2014/268479. Epub 2014 Apr 10.
2
A novel bispecific, trivalent antibody construct for targeting pancreatic carcinoma.一种用于靶向胰腺癌的新型双特异性三价抗体构建体。
Cancer Res. 2008 Jun 15;68(12):4819-26. doi: 10.1158/0008-5472.CAN-08-0232.
3
PAM4-reactive MUC1 is a biomarker for early pancreatic adenocarcinoma.PAM4反应性MUC1是早期胰腺腺癌的生物标志物。
Clin Cancer Res. 2007 Dec 15;13(24):7380-7. doi: 10.1158/1078-0432.CCR-07-1488.
4
Mapping PAM4 (clivatuzumab), a monoclonal antibody in clinical trials for early detection and therapy of pancreatic ductal adenocarcinoma, to MUC5AC mucin.将处于临床试验阶段的用于胰腺导管腺癌的早期检测和治疗的单克隆抗体 clivatuzumab（帕马珠单抗）映射到 MUC5AC 粘蛋白上。
Mol Cancer. 2013 Nov 20;12(1):143. doi: 10.1186/1476-4598-12-143.
5
Low-dose radioimmunotherapy ((90)Y-PAM4) combined with gemcitabine for the treatment of experimental pancreatic cancer.低剂量放射免疫疗法（（90）Y-PAM4）联合吉西他滨治疗实验性胰腺癌。
Clin Cancer Res. 2003 Sep 1;9(10 Pt 2):3929S-37S.
6
Localization of pancreatic cancer with radiolabeled monoclonal antibody PAM4.用放射性标记的单克隆抗体PAM4对胰腺癌进行定位
Crit Rev Oncol Hematol. 2001 Jul-Aug;39(1-2):147-54. doi: 10.1016/s1040-8428(01)00114-7.
7
Initial tumor targeting, biodistribution, and pharmacokinetic evaluation of the monoclonal antibody PAM4 in patients with pancreatic cancer.单克隆抗体PAM4在胰腺癌患者中的初始肿瘤靶向性、生物分布及药代动力学评估。
Cancer Res. 1995 Dec 1;55(23 Suppl):5911s-5915s.
8
Differentiation of pancreatic ductal adenocarcinoma from chronic pancreatitis by PAM4 immunohistochemistry.PAM4 免疫组化在胰腺导管腺癌与慢性胰腺炎鉴别诊断中的作用。
Arch Pathol Lab Med. 2014 Feb;138(2):220-8. doi: 10.5858/arpa.2013-0056-OA.
9
Combined gemcitabine and radioimmunotherapy for the treatment of pancreatic cancer.吉西他滨与放射免疫疗法联合治疗胰腺癌。
Int J Cancer. 2002 Jan 20;97(3):386-92. doi: 10.1002/ijc.1613.
10
Therapeutic advantage of (90)yttrium- versus (131)iodine-labeled PAM4 antibody in experimental pancreatic cancer.钇-90与碘-131标记的PAM4抗体在实验性胰腺癌中的治疗优势
Clin Cancer Res. 2001 Oct;7(10):3186-92.
引用本文的文献
1
The Oncoprotein Mucin 1 in Pancreatic Cancer Onset and Progression: Potential Clinical Implications.癌蛋白粘蛋白1在胰腺癌发生和发展中的作用：潜在的临床意义
Biomolecules. 2025 Feb 13;15(2):275. doi: 10.3390/biom15020275.
2
B cells in pancreatic cancer stroma.胰腺癌基质中的 B 细胞。
World J Gastroenterol. 2022 Mar 21;28(11):1088-1101. doi: 10.3748/wjg.v28.i11.1088.
3
Pancreatic cancer and adaptive metabolism in a nutrient-deficient environment.营养缺乏环境下的胰腺癌与适应性代谢
Cent Eur J Immunol. 2021;46(3):388-394. doi: 10.5114/ceji.2021.109693. Epub 2021 Oct 6.
4
Mucins in pancreatic cancer: A well-established but promising family for diagnosis, prognosis and therapy.胰腺癌细胞黏蛋白：一个成熟但有前途的家族，可用于诊断、预后和治疗。
J Cell Mol Med. 2020 Sep;24(18):10279-10289. doi: 10.1111/jcmm.15684. Epub 2020 Aug 3.
5
Evaluation of novel highly specific antibodies to cancer testis antigen Centrin-1 for radioimmunoimaging and radioimmunotherapy of pancreatic cancer.评估新型高度特异性的癌症睾丸抗原 Centrin-1 抗体用于胰腺癌的放射免疫显像和放射免疫治疗。
Cancer Med. 2019 Sep;8(11):5289-5300. doi: 10.1002/cam4.2379. Epub 2019 Jul 16.
6
Advances in pancreatic cancer biomarkers.胰腺癌生物标志物的进展。
Oncol Rev. 2019 Feb 1;13(1):410. doi: 10.4081/oncol.2019.410. eCollection 2019 Jan 14.
7
Cancer-associated mucins: role in immune modulation and metastasis.癌症相关粘蛋白：在免疫调节和转移中的作用。
Cancer Metastasis Rev. 2019 Jun;38(1-2):223-236. doi: 10.1007/s10555-018-09775-0.
8
High expression of RAB38 promotes malignant progression of pancreatic cancer.RAB38 的高表达促进了胰腺癌的恶性进展。
Mol Med Rep. 2019 Feb;19(2):909-918. doi: 10.3892/mmr.2018.9732. Epub 2018 Dec 10.
9
Mucins in pancreatic cancer: biological role, implications in carcinogenesis and applications in diagnosis and therapy.胰腺癌中的黏蛋白：生物学作用、在致癌过程中的意义及在诊断和治疗中的应用
Am J Cancer Res. 2017 Jun 1;7(6):1372-1383. eCollection 2017.
10
Targeted Radionuclide Therapy of Human Tumors.人类肿瘤的靶向放射性核素治疗
Int J Mol Sci. 2015 Dec 28;17(1):33. doi: 10.3390/ijms17010033.
本文引用的文献
1
Mapping PAM4 (clivatuzumab), a monoclonal antibody in clinical trials for early detection and therapy of pancreatic ductal adenocarcinoma, to MUC5AC mucin.将处于临床试验阶段的用于胰腺导管腺癌的早期检测和治疗的单克隆抗体 clivatuzumab（帕马珠单抗）映射到 MUC5AC 粘蛋白上。
Mol Cancer. 2013 Nov 20;12(1):143. doi: 10.1186/1476-4598-12-143.
2
Carcinogenesis of pancreatic adenocarcinoma: precursor lesions.胰腺腺癌的癌变过程：前体病变。
Int J Mol Sci. 2013 Sep 30;14(10):19731-62. doi: 10.3390/ijms141019731.
3
Altered glycosylation of MUC1 influences its association with CIN85: the role of this novel complex in cancer cell invasion and migration.MUC1糖基化改变影响其与CIN85的结合：这种新型复合物在癌细胞侵袭和迁移中的作用。
Oncotarget. 2013 Oct;4(10):1686-97. doi: 10.18632/oncotarget.1265.
4
MUC1 activates JNK1 and inhibits apoptosis under genotoxic stress.黏蛋白 1 在遗传毒性应激下激活 JNK1 并抑制细胞凋亡。
Biochem Biophys Res Commun. 2013 Oct 11;440(1):179-83. doi: 10.1016/j.bbrc.2013.09.055. Epub 2013 Sep 18.
5
Precancerous lesions of the pancreas.胰腺的癌前病变。
Best Pract Res Clin Gastroenterol. 2013 Apr;27(2):299-322. doi: 10.1016/j.bpg.2013.04.001.
6
MUC1 induces drug resistance in pancreatic cancer cells via upregulation of multidrug resistance genes.MUC1 通过上调多药耐药基因诱导胰腺癌耐药。
Oncogenesis. 2013 Jun 17;2(6):e51. doi: 10.1038/oncsis.2013.16.
7
The epidemiology of pancreatitis and pancreatic cancer.胰腺炎和胰腺癌的流行病学。
Gastroenterology. 2013 Jun;144(6):1252-61. doi: 10.1053/j.gastro.2013.01.068.
8
Cancer statistics, 2013.癌症统计数据，2013 年。
CA Cancer J Clin. 2013 Jan;63(1):11-30. doi: 10.3322/caac.21166. Epub 2013 Jan 17.
9
Multimodality imaging of pancreatic cancer-computed tomography, magnetic resonance imaging, and positron emission tomography.胰腺癌的多模态影像学——计算机断层扫描、磁共振成像和正电子发射断层扫描。
Cancer J. 2012 Nov-Dec;18(6):511-22. doi: 10.1097/PPO.0b013e318274a461.
10
Current concepts and novel targets in advanced pancreatic cancer.晚期胰腺癌的当前概念和新靶点。
Gut. 2013 Feb;62(2):317-26. doi: 10.1136/gutjnl-2012-303588. Epub 2012 Oct 30.
Zotero 插件